Roivant Sciences Ltd. (ROIV)
| Market Cap | 30.32B +105.9% |
| Revenue (ttm) | 41.08M +102.1% |
| Net Income | -344.35M |
| EPS | -0.59 |
| Shares Out | 724.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,982,681 |
| Open | 41.47 |
| Previous Close | 41.19 |
| Day's Range | 40.86 - 42.24 |
| 52-Week Range | 19.96 - 42.50 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 50.36 (+20.34%) |
| Earnings Date | Nov 9, 2026 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rh... [Read more]
Financial Performance
In fiscal year 2026, Roivant Sciences's revenue was $8.26 million, a decrease of -71.57% compared to the previous year's $29.05 million. Losses were -$299.77 million, 74.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $50.36, which is an increase of 20.34% from the latest price.
News
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double...
Roivant Sciences price target raised to $48 from $47 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences (ROIV) to $48 from $47 and keeps a Buy rating on the shares. The firm says Lisraya’s…
Roivant Sciences price target raised to $42 from $41 at BofA
BofA raised the firm’s price target on Roivant Sciences (ROIV) to $42 from $41 and keeps a Neutral rating on the shares, citing higher Lisraya estimates and a higher valuation…
Roivant Sciences Earnings Call Transcript: Q2 2027
LISRAYA recorded $31 million in its first five weeks, while IMVT-1402 showed sustained RA responses at 600 mg. NIU and PH-ILD data strengthened the pipeline; cash was $4.2 billion at quarter-end.
Roivant Sciences Quarterly report: Q2 2027
Roivant Sciences has published its Q2 2027 quarterly earnings report on November 9, 2026.
Roivant Sciences Slides: Q2 2027
Roivant Sciences has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 9, 2026.
Roivant Sciences Earnings release: Q2 2027
Roivant Sciences released its Q2 2027 earnings on November 9, 2026, summarizing the period's financial results.
Roivant Sciences reports Q2 EPS (27c), consensus (45c)
Reports Q2 revenue $35.12M, consensus $4.11M. Product revenue, net was $31M for the three months ended September 30, consisting of net product revenue from sales of Lisraya in its first…
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response ...
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially re...
Roivant Sciences price target raised to $56 from $46 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Roivant Sciences (ROIV) to $56 from $46 and keeps a Buy rating on the shares ahead of the Q3 report.
Roivant Sciences price target raised to $62 from $55 at TD Cowen
TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $62 from $55 and keeps a Buy rating on the shares after “spectacular” Phase 3 data for brepocitinib…
Roivant Sciences Transcript: Study result
In two phase III CLARITY trials, brepocitinib delayed treatment failure through 48 weeks and increased steroid-free quiescence versus placebo. Macular edema and vision-related outcomes also improved; an NIU sNDA is planned for H1 2027.
Roivant Sciences Press release: Study result
Roivant Sciences issued a press release on October 21, 2026, disclosing material business information to investors.
Roivant Sciences Slides: Study result
Roivant Sciences has posted slides in relation to its latest quarterly earnings report, which was published on October 21, 2026.
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 CLARITY...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, Nov...
Citi opens ‘upside 90-day catalyst watch’ on Roivant Sciences
Citi analyst Samantha Semenkow added an “upside 90-day catalyst watch” on Roivant Sciences (ROIV) while keeping a Buy rating on the shares with a $46 price target The Phase 3…
Roivant Sciences downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Roivant Sciences (ROIV) to Peer Perform from Outperform with no price target The stock profile is changing, with good catalysts “now more scarce” and a “stretched valuation,”...
Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback
H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity ...
Roivant Sciences price target raised to $41 from $37.50 at BofA
BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and keeps a Neutral rating on the shares after having hosted CEO Matt…
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Roivant Sciences Transcript: Bank of America Global Healthcare Conference
Recent milestones include positive phase II data for mosliciguat and the launch of LISRAYA in dermatomyositis, with more clinical readouts expected soon. Focus is on commercialization, expanding indications, and advancing FcRn programs, especially in autoimmune and orphan diseases like Graves' disease and non-infectious uveitis.
Roivant Sciences initiated with a Buy at Stifel
Stifel initiated coverage of Roivant Sciences (ROIV) with a Buy rating and $51 price target The company offers a “compelling multi-asset story with scarcity value” within the specialty autoimmune and…